Phase I Clinical Trial of DNA Methyltransferase Inhibitor Decitabine and PARP Inhibitor Talazoparib Combination Therapy in Relapsed/Refractory Acute Myeloid Leukemia.

Maria R BaerAksinija A KoganSøren M BentzenTian MiRena G LapidusVu H DuongAshkan EmadiSandrine NiyongereCasey L O'ConnellBenjamin A YoungbloodStephen B BaylinFeyruz V Rassool

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)

Decitabine/talazoparib combination was well tolerated. Expected pharmacodynamic effects occurred, especially in responders.

Keyphrases

acute myeloid leukemia
combination therapy
clinical trial
allogeneic hematopoietic stem cell transplantation
dna damage
single molecule
dna repair
cell free
study protocol
phase ii
double blind
oxidative stress
diffuse large b cell lymphoma
randomized controlled trial
phase iii